Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: W.R. Grace

This article was originally published in The Gray Sheet

Executive Summary

W.R. Grace: Announces June 14 that it plans to spin off its National Medical Care kidney dialysis services unit by issuing a special stock dividend to Grace shareholders. Grace's board chose the tax-free spin-off over several takeover bids, including a $3.5 bil. offer made by NMC Chairman/CEO Constantine Hampers in early May ("The Gray Sheet" May 8, p. 14) and a more recent proposal by Vivra, an NMC competitor in the kidney dialysis services field. In conjunction with the deal, NMC will pay Grace a $1.4 bil. one-time dividend. Grace President/CEO Albert Costello said the spin-off will make Grace "a strategically, operationally and financially stronger company." Grace, which had $5.1 bil. in sales during 1994 including $1.9 bil. from NMC, also has retained Arthur Andersen & Co. to help it reduce operating costs.

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel